ONCOMATRYX
Developing Quantum ADCs against the tumor microenvironment for innovative cancer therapies.
About
ONCOMATRYX is a Spanish biopharmaceutical company focused on developing innovative cancer therapies. They specialize in Quantum ADCs (Antibody-Drug Conjugates) designed to target the tumor microenvironment. The company has recently secured significant funding to advance the clinical development of its novel drug candidates. Teams look it up for Biotechnology, Pharmaceuticals, Healthcare.
Frequently asked
What does ONCOMATRYX do?
ONCOMATRYX is a Biotechnology company that offers Services. Teams look it up for Pharmaceuticals, Healthcare, Biotech. It is based in Derio, Spain and was founded in 2009. Public records show about 36 people and $107M raised. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has ONCOMATRYX raised?
ONCOMATRYX has raised a total of $107M in funding. The most recent round on record is Funding Round.
Where is ONCOMATRYX headquartered?
ONCOMATRYX is headquartered in Derio, Spain.
When was ONCOMATRYX founded?
ONCOMATRYX was founded in 2009.
What industry does ONCOMATRYX operate in?
ONCOMATRYX operates in Biotechnology, Pharmaceuticals, Healthcare, Biotech, Drug Discovery.
How many employees does ONCOMATRYX have?
ONCOMATRYX has approximately 36 people on record.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.